Personalis shares rise 5% in premarket trading after receiving a $13.5M task order from the Department of Veterans Affairs. The order is under a contract with the VA and marks a significant milestone for the cancer test maker. The company's stock has increased in value following the announcement.
Personalis Inc. (NASDAQ: PSNL) saw its stock rise by approximately 5% in premarket trading on Friday following the announcement that it had received a new task order worth up to $13.5 million from the Department of Veterans Affairs (VA). The order is part of the VA Million Veteran Program (MVP), a large-scale population sequencing initiative [1].
The task order, which takes effect on September 30, 2025, subject to the receipt of samples and the fulfillment of services, is a significant milestone for the cancer test maker. Personalis, known for its NeXT Personal cancer test, provides genome sequencing services as part of the VA MVP contract. This new order is expected to contribute to the company's ongoing revenue growth.
To date, Personalis has received nearly $225 million in task orders under its contracts with the VA MVP, which accounted for 9% of its topline in 2024 and 13% in 2023, respectively [1]. The company has been focusing on expanding its presence in the VA MVP program, which has shown strong potential for growth.
The latest order comes as the company continues to refine its strategic focus and expand its service offerings. Personalis reported its Q2 2025 earnings call, outlining a $70 million to $80 million revenue target for the year, along with a 59% sequential clinical test growth and a revised biopharma outlook [1].
In the current financial climate, investors are closely monitoring Personalis' performance, particularly its ability to secure large-scale contracts and execute on its strategic goals. The latest VA MVP task order is a positive indicator of the company's market position and its potential for future growth.
References:
[1] https://seekingalpha.com/news/4488258-personalis-stock-gains-va-work-order
Comments
No comments yet